Impact of semaglutide on weight and functional outcomes among obese heart failure patients: a propensity scores matching analysis
Semaglutide was associated with significant weight reduction in obese patients with heart failure, accompanied by improved NYHA classification and 6-minute walk distance. Larger, multi-center trials and prospective, randomized controlled trials are warranted. These studies should focus on assessing long-term outcomes, optimizing dosage, and exploring the potential cardiovascular benefits beyond weight reduction.
Authors
- Marc Ulrich Becher (ORCID: https://orcid.org/0000-0002-6653-5046)
- Mahmoud Balata (ORCID: https://orcid.org/0000-0003-4744-1703)
Institutions
- University Hospital Bonn (DE)
- Städtisches Klinikum Solingen (DE)
Publication Details
- Journal
- BMC Cardiovascular Disorders
- Published
- 2024-10-26
- DOI
- https://doi.org/10.1186/s12872-024-04275-2
- Citations
- 3
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 1.07